Cancer Pain – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report

Cancer pain is a common experience for many individuals diagnosed with cancer or undergoing cancer treatment. The primary cause of cancer pain is the tumor, which can compress surrounding tissues such as nerves, bones, spinal cord, and organs. It can also result from diagnostic tests or treatments, such as biopsies, spinal taps, radiation therapy, chemotherapy, and surgery. The pain can be either acute or chronic. Acute pain is typically short-lived due to injury or treatment, while chronic pain can be persistent and may result from nerve changes due to cancer or cancer treatment. The World Health Organization has developed a three-step analgesia guide for cancer pain management, which includes non-opioids, weak opioids, and strong opioids.
• Pain prevalence rates were 39.3% after curative treatment, 55.0% during anticancer treatment, and 66.4% in advanced, metastatic, or terminal disease.

Thelansis’s “Cancer Pain Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Cancer Pain treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Cancer Pain across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Cancer Pain Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Cancer Pain – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033